Viewing StudyNCT00207168



Ignite Creation Date: 2024-05-05 @ 11:59 AM
Last Modification Date: 2024-10-26 @ 9:18 AM
Study NCT ID: NCT00207168
Status: COMPLETED
Last Update Posted: 2011-04-22
First Post: 2005-09-12

Brief Title: To Assess Compliance With a Once-daily Regimen of Lamivudine Efavirenz and Didanosine
Sponsor:
Organization: Bristol-Myers Squibb

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 120
Enrollment Type: None
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE4
Observational Models:
Time Perspective List:
Who Masked List: